Oral cancer: Early detection can help boost chances of survival

The problem in India is that people ignore the early signs of cancer and they only consult a doctor when the cancer has reached the third or the fourth stage.
Cancer has many warning signs that can help detect the onset of the disease before it's too late.
With the present times experiencing a boost in medical advancements, it has become easier and smoother to detect a disease in its early stages and increase the patient's chances of survival.
Educating and promoting early diagnosis and spreading awareness on the various screening processes are the two major components of early detection of cancer.
Doing this, can help decrease the mortality rate as well as improve prognosis. Oral cancer or mouth cancer comes under a wide umbrella of Head and Neck cancers, which is caused due to abnormal tissue growth in the oral cavity.
Oral cancer is a major health complication, especially in the Indian sub-continent. It ranks among the top three types of cancer accounting to over 30 percent of all cancers.
Dr Vikram Kekatpure, senior consultant – Head and Neck Surgical Oncology, Cytecare Hospital, has cited that this type of cancer is commonly caused due to excessive smoking, and chewing of tobacco (gutkha). Alcohol consumption, poor oral hygiene and ill-fitting dentures add risk factors. Oral Cancer is not gender specific and can be seen in both men and women in India. This is a common disease in both the genders as now, both men as well as women are induced to tobacco addiction.
He further identifies, the primary symptoms of oral cancer can be identified when one notices red or white patches in the mouth cavity, i.e., tongue, gums or at the side of the mouth. Ulcers that do not get cured within three weeks should not be ignored since they could be early signs of oral cancer. On detecting these patches or ulcers, one must visit a dentist or a surgeon for immediate consultation.
Another reason of increasing deaths resulting from oral cancer in India is delayed detection. If detected at an initial stage, oral cancer has good chances of getting cured. The problem in India is that people ignore the early signs of cancer and they only consult a doctor when the cancer has reached the third or the fourth stage.
Dr Kekatpure adds treating any cancer in their latter stages can be extremely difficult. It is seen that people from the lower socio-economic strata are exposed to oral cancer more, because of their tobacco chewing habits. To avoid these complications, dentists or health workers must conduct screening programs at a community level, especially in small towns and rural areas where tobacco users are high in numbers. These screening programs will help spread awareness among people in tier two and tier three cities and towns.
Oral Cancer treatment is a social and economic burden in India, especially for Individuals who belong to the lower economic strata. Treatments of earlier detected cancer have less economic burden and have more chances of long term survival.
In stages one and two, most oral cancer patients are successfully treated with surgery alone however in stages three and four a combination treatment with surgery followed by radiation and chemotherapy may be required.
Hence, early detection of oral cancer results in positive healing of the disease. We need to create awareness regarding harmful effects of tobacco consumption and help citizens become more conscious of the advantages of early detection to avoid harmful consequences in the future.
Source: http://zeenews.india.com/health/oral-cancer-early-detection-can-help-boost-chances-of-survival-1998434

Comments

Post a Comment

Popular posts from this blog

EMA validates Incyte’s MAA for retifanlimab to treat metastatic squamous cell anal carcinoma

Incyte, global biopharmaceutical company, announced the validation of the Company’s Marketing Authorization Application (MAA) for retifanlimab, an intravenous PD-1 inhibitor, as a potential treatment for adult patients with locally advanced or metastatic squamous cell anal carcinoma (SCAC) who have progressed on, or who are intolerant of, platinum-based chemotherapy. The European Medicines Agency’s (EMA) validation of the MAA confirms that the submission is sufficiently complete to begin the formal review process. “While the incidence of SCAC is increasing in Europe, treatment options for advanced disease are limited in their effectiveness, and there are no approved options once patients have progressed on standard therapy,” said Lance Leopold, M.D., Group vice president, Immuno-Oncology Clinical Development, Incyte. “The EMA validation of the MAA for retifanlimab – which follows the recent US Food & Drug Administration acceptance of our Biologics License Application for Priority R...
Read more

Tumour-targeting drug paves way for bone cancer treatment

 The treatment of osteosarcoma, the most common tumour of bone, is challenging, but a new study is offering hope to the patients with this disease. The study led by The University of  Texas MD Anderson Cancer Centre  found that a drug, known as bone metastasis-targeting peptidomimetic (BMTP-11), has potential as a new therapeutic strategy for this devastating illness. Results from the preclinical study looked at BMTP-11 alone and in combination with the chemotherapy agent gemcitabine. Although osteosarcoma is a relatively rare cancer, it is a leading disease-related cause of death in children and young adults ages 10 to 20. However, over the last 25 years, the five-year survival rate has remained unchanged, and the treatment options for these patients are few. In addition, the side effects of available treatment options often are significant and cumulative, and may cause other health problems and damage to major organs. "What's novel about this treatment is that...
Read more

Merck’s Keytruda plus platinum- and fluoropyrimidine-based chemotherapy receives US FDA nod to treat certain patients with locally advanced/metastatic esophageal or GEJ carcinoma

Merck, known as MSD outside the United States and Canada, announced that the US Food and Drug Administration (FDA) has approved Keytruda, Merck’s anti-PD-1 therapy, for the treatment of patients with locally advanced or metastatic esophageal or gastroesophageal junction (GEJ) (tumors with epicenter 1 to 5 centimeters above the GEJ) carcinoma that is not amenable to surgical resection or definitive chemoradiation in combination with platinum- and fluoropyrimidine-based chemotherapy. The approval is based on results from the phase 3 KEYNOTE-590 trial, which demonstrated significant improvements in overall survival (OS), progression-free survival (PFS) and objective response rate (ORR) for Keytruda plus fluorouracil (FU) and cisplatin versus FU and cisplatin alone, regardless of histology or PD-L1 expression status. For OS and PFS, Keytruda plus FU and cisplatin reduced the risk of death by 27% (HR=0.73 [95% CI, 0.62-0.86]; p<0.0001) and reduced the risk of disease progression or death...
Read more